Ascendis Pharma A/S (ASND) vs Elanco Animal Health (ELAN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Elanco Animal Health (ELAN) has outperformed Ascendis Pharma A/S (ASND) over the past year, gaining 9.3% versus a gain of 8.8%. Over five years, ASND leads with a +42.8% price change compared with -31.3% for ELAN. Ascendis Pharma A/S is the larger company by market cap ($14.65 billion vs $11.26 billion), about 1.3 times the size.
On valuation, Elanco Animal Health trades at a lower forward P/E (17.5x vs 20.6x for Ascendis Pharma A/S).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASND | ELAN |
|---|---|---|
| Share price | $222.69 | $22.54 |
| Market cap | $14.65B | $11.26B |
| 1-day change | -2.50% | +0.81% |
| YTD return | +7.11% | -1.19% |
| 1-year return | +8.84% | +9.34% |
| 5-year return | +42.77% | -31.28% |
| P/E ratio (TTM) | 17.06 | — |
| Forward P/E | 20.58 | 17.54 |
| EPS (TTM) | $13.05 | $-0.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $4.71B |
| Revenue growth (YoY) | — | +6.22% |
| Net income (latest FY) | — | $-232.00M |
| Gross margin | — | 54.99% |
| Net margin | — | -4.92% |
| 52-week high | $282.15 | $27.98 |
| 52-week low | $186.05 | $19.40 |
| Distance from 52-week high | -21.07% | -19.44% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +37.34% | +37.53% |
| Average volume | 658.78K | 6.18M |
| Shares outstanding | 65.80M | 499.45M |
| Employees | 1,189 | 9,400 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Ascendis Pharma A/S
ASND stock →Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,189 employees
About Elanco Animal Health
ELAN stock →Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark.
Health Care · Biotechnology: Pharmaceutical Preparations · 9,400 employees
ASND vs ELAN FAQ
Which is bigger, Ascendis Pharma A/S or Elanco Animal Health?
Ascendis Pharma A/S (ASND) is larger, with a market capitalization of $14.65B compared with $11.26B for Elanco Animal Health (ELAN).
Which stock has performed better over the past year, ASND or ELAN?
ELAN returned +9.34% over the past 12 months, compared with +8.84% for ASND (price return, excluding dividends). Past performance does not predict future results.
Are Ascendis Pharma A/S and Elanco Animal Health in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.